CS208147B2 - Method of making the stabile low antigennous or the antigene of the plain insuline preparation of the protracted effect - Google Patents
Method of making the stabile low antigennous or the antigene of the plain insuline preparation of the protracted effect Download PDFInfo
- Publication number
- CS208147B2 CS208147B2 CS76270A CS27076A CS208147B2 CS 208147 B2 CS208147 B2 CS 208147B2 CS 76270 A CS76270 A CS 76270A CS 27076 A CS27076 A CS 27076A CS 208147 B2 CS208147 B2 CS 208147B2
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- insulin
- solution
- preparation
- bovine
- buffer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
- C07K14/625—Extraction from natural sources
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK8375AA DK140801B (da) | 1975-01-15 | 1975-01-15 | Fremgangsmåde til fremstilling af et stabilt langtidsvirkende insulinpræparat. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS208147B2 true CS208147B2 (en) | 1981-08-31 |
Family
ID=8089535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS76270A CS208147B2 (en) | 1975-01-15 | 1976-01-15 | Method of making the stabile low antigennous or the antigene of the plain insuline preparation of the protracted effect |
Country Status (36)
| Country | Link |
|---|---|
| JP (1) | JPS5946939B2 (pt) |
| AR (1) | AR213088A1 (pt) |
| AT (1) | AT362492B (pt) |
| BE (1) | BE837600A (pt) |
| BR (1) | BR7600206A (pt) |
| CA (1) | CA1094549A (pt) |
| CH (1) | CH631625A5 (pt) |
| CS (1) | CS208147B2 (pt) |
| DD (1) | DD124379A5 (pt) |
| DE (1) | DE2600971C2 (pt) |
| DK (1) | DK140801B (pt) |
| EG (1) | EG11988A (pt) |
| ES (1) | ES444558A1 (pt) |
| FI (1) | FI66751C (pt) |
| FR (1) | FR2297634A1 (pt) |
| GB (1) | GB1524431A (pt) |
| GR (1) | GR58608B (pt) |
| HU (1) | HU175142B (pt) |
| IE (1) | IE42395B1 (pt) |
| IL (1) | IL48845A (pt) |
| IN (1) | IN143279B (pt) |
| IT (1) | IT1054211B (pt) |
| KE (1) | KE2919A (pt) |
| LU (1) | LU74175A1 (pt) |
| MX (1) | MX4052E (pt) |
| MY (1) | MY7900169A (pt) |
| NL (1) | NL166464C (pt) |
| NO (1) | NO146698C (pt) |
| NZ (1) | NZ179733A (pt) |
| OA (1) | OA05209A (pt) |
| PL (1) | PL99927B1 (pt) |
| PT (1) | PT64696B (pt) |
| RO (1) | RO71576A (pt) |
| SE (1) | SE437219B (pt) |
| YU (1) | YU8376A (pt) |
| ZA (1) | ZA7658B (pt) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK374579A (da) * | 1979-09-07 | 1981-03-08 | Nordisk Insulinlab | Fremgangsmaade til fremstilling af et injucerbart insulinpraeparat |
| US4459226A (en) * | 1982-02-26 | 1984-07-10 | Eli Lilly And Company | Process for recovering insulin |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4878892A (en) * | 1987-02-10 | 1989-11-07 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of polypeptides |
| AU609769B2 (en) * | 1987-02-10 | 1991-05-09 | Drug Delivery Systems Inc. | Electrolytic transdermal delivery of proteins |
| US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5447728A (en) | 1992-06-15 | 1995-09-05 | Emisphere Technologies, Inc. | Desferrioxamine oral delivery system |
| US6221367B1 (en) | 1992-06-15 | 2001-04-24 | Emisphere Technologies, Inc. | Active agent transport systems |
| US5643957A (en) | 1993-04-22 | 1997-07-01 | Emisphere Technologies, Inc. | Compounds and compositions for delivering active agents |
| US5750147A (en) | 1995-06-07 | 1998-05-12 | Emisphere Technologies, Inc. | Method of solubilizing and encapsulating itraconazole |
| US6051258A (en) | 1995-06-07 | 2000-04-18 | Emisphere Technologies, Inc. | Proteinoid emulsions and methods for preparation and use thereof |
| EP2077132A1 (en) | 2008-01-02 | 2009-07-08 | Boehringer Ingelheim Pharma GmbH & Co. KG | Dispensing device, storage device and method for dispensing a formulation |
| EP2414560B1 (de) | 2009-03-31 | 2013-10-23 | Boehringer Ingelheim International GmbH | Verfahren zur beschichtung einer oberfläche eines bauteils |
| JP5763053B2 (ja) | 2009-05-18 | 2015-08-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | アダプタ、吸入器具及びアトマイザ |
| US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2011064163A1 (en) | 2009-11-25 | 2011-06-03 | Boehringer Ingelheim International Gmbh | Nebulizer |
| PE20130036A1 (es) | 2009-11-25 | 2013-02-03 | Boehringer Ingelheim Int | Nebulizador |
| JP5874724B2 (ja) | 2010-06-24 | 2016-03-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| WO2012130757A1 (de) | 2011-04-01 | 2012-10-04 | Boehringer Ingelheim International Gmbh | Medizinisches gerät mit behälter |
| US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
| WO2013152894A1 (de) | 2012-04-13 | 2013-10-17 | Boehringer Ingelheim International Gmbh | Zerstäuber mit kodiermitteln |
| JP6643231B2 (ja) | 2013-08-09 | 2020-02-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ネブライザ |
| PL2835146T3 (pl) | 2013-08-09 | 2021-04-06 | Boehringer Ingelheim International Gmbh | Nebulizator |
| CN106255554B (zh) | 2014-05-07 | 2021-05-04 | 勃林格殷格翰国际有限公司 | 容器、喷雾器及用途 |
| DK3139984T3 (da) | 2014-05-07 | 2021-07-19 | Boehringer Ingelheim Int | Forstøver |
| ES2957901T3 (es) | 2014-05-07 | 2024-01-29 | Boehringer Ingelheim Int | Recipiente y dispositivo indicador y nebulizador |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1285023A (en) * | 1968-08-09 | 1972-08-09 | Novo Terapeutisk Labor As | Improvements in or relating to injectable insulin preparations |
| US3758683A (en) * | 1971-04-30 | 1973-09-11 | R Jackson | Insulin product |
-
1975
- 1975-01-15 DK DK8375AA patent/DK140801B/da not_active IP Right Cessation
-
1976
- 1976-01-06 ZA ZA00760058A patent/ZA7658B/xx unknown
- 1976-01-07 GR GR49734A patent/GR58608B/el unknown
- 1976-01-07 IN IN41/CAL/76A patent/IN143279B/en unknown
- 1976-01-12 NZ NZ179733A patent/NZ179733A/xx unknown
- 1976-01-12 FI FI760058A patent/FI66751C/fi not_active IP Right Cessation
- 1976-01-12 CA CA243,587A patent/CA1094549A/en not_active Expired
- 1976-01-13 IT IT19221/76A patent/IT1054211B/it active
- 1976-01-13 DE DE2600971A patent/DE2600971C2/de not_active Expired
- 1976-01-13 LU LU74175A patent/LU74175A1/xx unknown
- 1976-01-13 SE SE7600284A patent/SE437219B/xx not_active IP Right Cessation
- 1976-01-13 IE IE62/76A patent/IE42395B1/en unknown
- 1976-01-14 NO NO760118A patent/NO146698C/no unknown
- 1976-01-14 BR BR7600206A patent/BR7600206A/pt unknown
- 1976-01-14 PT PT64696A patent/PT64696B/pt unknown
- 1976-01-14 DD DD190805A patent/DD124379A5/xx unknown
- 1976-01-14 GB GB1309/76A patent/GB1524431A/en not_active Expired
- 1976-01-14 YU YU00083/76A patent/YU8376A/xx unknown
- 1976-01-14 PL PL1976186526A patent/PL99927B1/pl unknown
- 1976-01-14 FR FR7600854A patent/FR2297634A1/fr active Granted
- 1976-01-14 MX MX764822U patent/MX4052E/es unknown
- 1976-01-14 AT AT21376A patent/AT362492B/de not_active IP Right Cessation
- 1976-01-14 RO RO7684491A patent/RO71576A/ro unknown
- 1976-01-14 OA OA55703A patent/OA05209A/xx unknown
- 1976-01-14 NL NL7600338.A patent/NL166464C/xx not_active IP Right Cessation
- 1976-01-15 CH CH47076A patent/CH631625A5/de not_active IP Right Cessation
- 1976-01-15 HU HU76NO198A patent/HU175142B/hu unknown
- 1976-01-15 BE BE163542A patent/BE837600A/xx not_active IP Right Cessation
- 1976-01-15 IL IL48845A patent/IL48845A/xx unknown
- 1976-01-15 ES ES444558A patent/ES444558A1/es not_active Expired
- 1976-01-15 CS CS76270A patent/CS208147B2/cs unknown
- 1976-01-16 JP JP51003293A patent/JPS5946939B2/ja not_active Expired
- 1976-01-17 EG EG16/76A patent/EG11988A/xx active
-
1978
- 1978-01-14 AR AR261924A patent/AR213088A1/es active
-
1979
- 1979-02-07 KE KE2919A patent/KE2919A/xx unknown
- 1979-12-30 MY MY169/79A patent/MY7900169A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CS208147B2 (en) | Method of making the stabile low antigennous or the antigene of the plain insuline preparation of the protracted effect | |
| US4183849A (en) | Therapeutic insulin preparation and a process for the production of a stable insulin preparation with protracted effect | |
| Striessnig et al. | Identification of a phenylalkylamine binding region within the alpha 1 subunit of skeletal muscle Ca2+ channels. | |
| AU627423B2 (en) | Human somatomedin carrier protein subunits and process for producing them | |
| EP0197901A1 (en) | Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations | |
| EP0424416B1 (en) | Acid-labile subunit (als) of insulin-like-growth factor (igf) binding protein complex | |
| Gold et al. | Biochemical and immunological characterization of three binding sites on human plasma fibronectin with different affinities for heparin | |
| Baseler et al. | Purification of haptoglobin and its effects on lymphocyte and alveolar macrophage responses | |
| EP0462192A1 (en) | Glycosylated insulins | |
| JPH04503154A (ja) | 変型ヒト成長ホルモン | |
| JP2710645B2 (ja) | ｓｎＲＮＰ−Ａ抗原及びそのフラグメント | |
| Shemer et al. | Insulin receptors in lizard brain and liver: structural and functional studies of α and β subunits demonstrate evolutionary conservation | |
| Stevens et al. | Chick calretinin: purification, composition, and metal binding activity of native and recombinant forms | |
| US7485622B2 (en) | Paralytic peptide for use in neuromuscular therapy | |
| Permiakov et al. | Parvalbumin | |
| Lundwall et al. | Isolation of tryptic fragments of human C4 expressing Chido and Rodgers antigens | |
| CZ389397A3 (cs) | Stimulační faktor kostí | |
| CA1108535A (en) | Protein and process for isolating it | |
| Bergstrand et al. | Antigenic determinants in the N-terminal part of bovine encephalitogenic protein studied with the macrophage migration inhibition assay in guinea pigs. Evidence for an immunological reactivity of peptide 1–43 when tested on cells from animals injected with Freund's complete adjuvant | |
| Ingham et al. | Ligand-induced self-association of human chorionic gonadotropin. Positive cooperativity in the binding of 8-anilino-1-naphthalenesulfonate | |
| Weiler et al. | Synthesis and characterization of a bioactive 82-residue sphingolipid activator protein, saposin C | |
| CS205040B2 (en) | Method of production of the water soluble,injected cross screened orgothein | |
| Watkins et al. | The immunological properties of proteins treated with di-2-chloroethylmethylamine | |
| Kelso et al. | Induction of hyperglycemia with insulin antibodies to B-chain determinants | |
| Huang et al. | Modulation of allosteric interactions in neurophysin induced by succinylation of serine-56 or cleavage of residues 1-8 |